| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |